HHS announces agreement to transition Paxlovid to commercial market

Oct 16, 2023 - 03:02 PM
hhs-health-and-human-services-seal

The Department of Health and Human Services in November will begin transitioning to commercial distribution an estimated 7.9 million treatment courses of the COVID-19 antiviral pill Paxlovid under an agreement with Pfizer announced. Authorized for emergency use, the supply will remain available for ordering from HHS through Dec. 15, 2023. Beginning in 2024, Pfizer will sell Paxlovid to privately insured patients and operate a federal copay assistance program for these individuals through 2028. Pfizer also will continue to operate a federal assistance program to offer the HHS-procured supply without cost to eligible Medicare, Medicaid and uninsured patients through 2024 and to eligible uninsured and underinsured individuals from 2025 through 2028, updating any expired product. The company also will provide HHS with an additional 1 million treatment courses for the national stockpile. 

Related News Articles

Headline
View the AHA's latest United Against the Flu toolkit celebrating fall
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
CDC recommends two doses of COVID-19 vaccine for older individuals, lowers pneumococcal vaccine age 
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
CDC reminds hospital and health system workers to protect themselves, patients during respiratory virus season
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Chairperson's File
Chair File: The Best Defense Against Flu and COVID-19
Autumn is here, and that means cooler weather and also the start of flu season.We know the best way to prevent influenza is to get a flu vaccine. The Centers…
Headline
Survey: Less than 20% of U.S. adults concerned for themselves or family receiving infection ahead of respiratory virus season
The National Foundation for Infectious Diseases Sept. 25 released a survey showing that less than one in five U.S. adults are concerned about themselves or a…
Headline
FDA authorizes combination tests for flu, COVID-19
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-…